Month: August 2025

Earth Science Tech, Inc. Reports 61% Asset Growth to $7.69 Million and $8.7 Million in First Quarter Revenue Following Foundational Quarter of Strategic Acquisitions

Written by Customer Service on August 8, 2025. Posted in Public Companies.

MIAMI, FL, Aug. 08, 2025 (GLOBE NEWSWIRE) — MIAMI, FL – August 8, 2025 – Earth Science Tech, Inc. (OTC: ETST) (“ETST” or the “Company”), a strategic holding company focused on acquiring and scaling high-potential operating businesses, today announced its financial and operational results for the first fiscal quarter ended June 30, 2025. Giorgio R. Saumat, ETST’s CEO, commented: “The first quarter of fiscal 2025 was a pivotal period for Earth Science Tech. We strategically deployed capital to acquire high-potential operating businesses that are now poised to enhance our diversified product and service offerings. This was a foundational quarter, setting the stage for the future. Our focus has now firmly shifted from acquisitions to maximizing the value and profitability of our current divisions, ensuring we capitalize on these strategic...

Parks! America, Inc. Reports Third Quarter Fiscal Year 2025 Financial Results

Written by Customer Service on August 8, 2025. Posted in Public Companies.

Management to host conference call on Monday, August 11, 2025, at 4:30 PM ET PINE MOUNTAIN, Georgia, Aug. 08, 2025 (GLOBE NEWSWIRE) — Parks! America, Inc. (OTCQX: PRKA), today announced its financial results for the third fiscal quarter ended June 29, 2025. The summary information in this press release should not be used as the sole basis for making investment decisions. We encourage shareholders to read our complete Form 10-Q, which has been posted on the Investor Info section of the Company’s website, www.parksamerica.com, for a complete view of the Company and its results. Segment Financial Results for the 13 and 39 weeks ended June 29, 2025 The Company manages its operations on an individual location basis. Financial information regarding each of the Company’s reportable segments is summarized in the tables below. For...

Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results

Written by Customer Service on August 8, 2025. Posted in Earnings Releases And Operating Results.

TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) — Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and nine months ended June 30, 2025 and provided an update on its business. During the quarter, the company advanced manufacturing-related activities to support U.S. regulatory approval of a Phase 2 study of Edesa’s drug candidate EB06 (an anti-CXCL10 monoclonal antibody) in patients with moderate-to-severe nonsegmental vitiligo. Edesa anticipates drug manufacturing data for EB06 to be submitted to the U.S. Food and Drug Administration (FDA) for its investigational new drug (IND) application by the end of calendar 2025 based on the current availability of manufacturing slots at third...

Barnes & Noble Education Receives NYSE Notice Regarding Delayed 10-K Filing

Written by Customer Service on August 8, 2025. Posted in Public Companies.

BASKING RIDGE, N.J., Aug. 08, 2025 (GLOBE NEWSWIRE) — On August 4, 2025, Barnes & Noble Education, Inc. (NYSE: BNED) (the “Company”) received notice from the New York Stock Exchange (the “NYSE”) that the Company is not in compliance with Section 802.01E of the NYSE Listed Company Manual due to a delay in filing its Annual Report on Form 10-K for the fiscal year ended May 3, 2025 (the “Form 10-K”), with the Securities and Exchange Commission (the “SEC”). The Company determined that it would not be able to file the Form 10-K within the 15-day extension period under Rule 12b-25 without unreasonable effort or expense due to an audit committee internal investigation that rendered management unable to complete the Company’s financial reporting process and preparation of its financial statements for the fiscal year ended May 3, 2025....

Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights

Written by Customer Service on August 8, 2025. Posted in Earnings Releases And Operating Results.

Presented preclinical data at the American Society of Clinical Oncology (ASCO) on CLD-401 demonstrating biological efficacy IL-15 superagonist delivery to metastatic tumor sites and reduced immune clearance through engineered CD55 membrane expression; IND filing expected by the end of 2026 Received FDA Fast Track Designation for CLD-201, a first-in-class stem-cell loaded intratumoral viral therapy for the treatment of patients with soft tissue sarcoma Raised $4.6 million gross proceeds through a warrant inducement offering with existing investors that further strengthens the company’s balance sheet and extends its runwaySAN DIEGO, Aug. 08, 2025 (GLOBE NEWSWIRE) — Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential...

NI Holdings, Inc. Reports Results for Second Quarter Ended June 30, 2025

Written by Customer Service on August 8, 2025. Posted in Earnings Releases And Operating Results.

FARGO, N.D., Aug. 08, 2025 (GLOBE NEWSWIRE) — NI Holdings, Inc. (NASDAQ: NODK) announced today results for the quarter ended June 30, 2025. Summary of Second Quarter 2025 Results – Continuing Operations(All comparisons vs. continuing operations for the second quarter of 2024, unless noted otherwise)Direct written premiums of $109.5 million compared to $118.5 million. This reduction was driven by Non-Standard Auto (-56.4%) due to the continued impact of the strategic decision to significantly decrease our Non-Standard Auto premiums, partially offset by Home and Farm (8.1%) driven by higher rate and insured values along with new business growth in North Dakota. Combined ratio of 125.1% versus 113.7%, primarily driven by higher unfavorable development of liability loss claims in Non-Standard Auto, decreased net earned premiums in...

Westwood Holdings Group, Inc. Reports Second Quarter 2025 Results

Written by Customer Service on August 8, 2025. Posted in Earnings Releases And Operating Results.

Assets Under Management totaled $18.3 billion, up from $16.8 billion last yearWHG joined the Russell 2000 Index in our 24th Year as a Public CompanyEnhanced Midstream Energy ETF (MDST) surpassed $100 million with a 10.2% p.a. Distribution RateWEBs Investments, in Partnership with WHG, Expands Defined Volatility℠ ETF Suite with Launch of 11 Sector Funds DALLAS, Aug. 08, 2025 (GLOBE NEWSWIRE) — Westwood Holdings Group, Inc. (NYSE: WHG) today reported second quarter 2025 earnings. Significant items included:Multiple investment strategies beating their primary benchmarks included SmallCap Value, AllCap Value, MidCap Value, Dividend Select, Alternative Income, Credit Opportunities, Enhanced Midstream Income and Enhanced Energy Income. AllCap Value posted a top third ranking vs. peers and MidCap Value, Credit Opportunities and Enhanced...

Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update

Written by Customer Service on August 8, 2025. Posted in Earnings Releases And Operating Results.

Daniel Chao, M.D., Ph.D., joins Surrozen as Vice President of Clinical Development Surrozen forms Clinical Advisory Board comprised of leading retinal specialists Data Presentations at Association for Research in Vision and Ophthalmology Annual Meeting and Clinical Trials at the Summit SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) — Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, with a focus on severe eye diseases, today announced financial results for the second quarter ended June 30, 2025, and provided a business update. Business Highlights Surrozen remains focused on its ophthalmology pipeline, leveraging its Wnt biology expertise and antibody technologies to develop...

Femasys Announces Second Quarter Financial Results for 2025

Written by Customer Service on August 8, 2025. Posted in Earnings Releases And Operating Results.

— Continued Progress on Regulatory Approvals and Global Commercialization of Fertility Portfolio — ATLANTA, Aug. 08, 2025 (GLOBE NEWSWIRE) — Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced its financial results for the second quarter of 2025. Corporate Highlights from 2Q 2025 to dateAnnounced European Union Medical Device Regulation approval of FemBloc®, the first global regulatory endorsement of our groundbreaking non-surgical permanent birth control solution Secured first European order for FemBloc from Spain distribution partners for approximately $400,000 Announced Australian and New Zealand regulatory approvals for FemaSeed® and FemVue®, a cost-effective first step in fertility Announced...

Phunware Reports Second Quarter 2025 Financial Results

Written by Customer Service on August 8, 2025. Posted in Earnings Releases And Operating Results.

Delivers Strong First Half with Key Product Milestones and Customer Momentum Strong Liquidity Powering New Technology Improvements, AI Integration and Corporate Initiatives AUSTIN, Texas, Aug. 08, 2025 (GLOBE NEWSWIRE) — Phunware, Inc. (“Phunware” or the “Company”) (NASDAQ: PHUN), a leader in enterprise cloud solutions for mobile applications, today reported financial results for the second quarter ended June 30, 2025. Financial HighlightsSoftware subscriptions and services revenue decreased 16% to $0.4 million in Q2 2025, as compared to Q2 2024. Q2 2025 software and subscription bookings totaled $0.6 million. Software subscriptions and services gross margin improved 1,694 basis points to 43.9% in Q2 2025 from 26.9% in Q2 2024. Net loss was $3.1 million for the three months ended June 30, 2025, compared to $2.6 million in the...

Month: August 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals